- Home
- SFWL vs VANI Comparison
SFWL vs VANI Comparison
Compare SFWL & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SFWL
- VANI
- Stock Information
- Founded
- SFWL 2001
- VANI 1998
- Country
- SFWL China
- VANI United States
- Employees
- SFWL N/A
- VANI N/A
- Industry
- SFWL Trucking Freight/Courier Services
- VANI Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- SFWL Industrials
- VANI Health Care
- Exchange
- SFWL Nasdaq
- VANI Nasdaq
- Market Cap
- SFWL 82.5M
- VANI 81.2M
- IPO Year
- SFWL 2023
- VANI 2014
- Fundamental
- Price
- SFWL $0.94
- VANI $1.67
- Analyst Decision
- SFWL
- VANI Strong Buy
- Analyst Count
- SFWL 0
- VANI 1
- Target Price
- SFWL N/A
- VANI $4.00
- AVG Volume (30 Days)
- SFWL 18.8K
- VANI 241.8K
- Earning Date
- SFWL 08-27-2025
- VANI 11-12-2025
- Dividend Yield
- SFWL N/A
- VANI N/A
- EPS Growth
- SFWL 31.68
- VANI N/A
- EPS
- SFWL 0.14
- VANI N/A
- Revenue
- SFWL $540,461,000.00
- VANI N/A
- Revenue This Year
- SFWL N/A
- VANI N/A
- Revenue Next Year
- SFWL N/A
- VANI N/A
- P/E Ratio
- SFWL $6.91
- VANI N/A
- Revenue Growth
- SFWL 21.10
- VANI N/A
- 52 Week Low
- SFWL $0.86
- VANI $0.91
- 52 Week High
- SFWL $1.60
- VANI $1.92
- Technical
- Relative Strength Index (RSI)
- SFWL 40.79
- VANI 61.20
- Support Level
- SFWL $0.93
- VANI $1.36
- Resistance Level
- SFWL $1.00
- VANI $1.92
- Average True Range (ATR)
- SFWL 0.04
- VANI 0.11
- MACD
- SFWL -0.00
- VANI 0.03
- Stochastic Oscillator
- SFWL 27.27
- VANI 59.02
About SFWL Shengfeng Development Limited
Shengfeng Development Ltd is a holding company. Through its subsidiaries, it offers contract logistics services in China. The contract logistics services offered by the company include planning and designing supply chains, designing facilities, processing orders, collecting payments, managing inventories, and providing client services.
About VANI Vivani Medical Inc. (DE)
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. The company develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd, and the Neurostimulation Division includes activities from Cortigent and its subsidiary in Switzerland.